Hepatorenal Syndrome

  • Solomon Papper

Abstract

The hepatorenal syndrome is a specific form of acute renal failure occurring in patients with parenchymal liver disease of diverse etiology.

Keywords

Ischemia Dopamine Angiotensin Norepinephrine Bilirubin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Flint A. Clinical report on hydro-peritoneum, based on an analysis of forty-six cases. Am J Med Sci 45: 306–339, 1863.CrossRefGoogle Scholar
  2. 2.
    Helwig FC, Schutz CB. A liver kidney syndrome. Clinical, pathological and experimental studies. Surg Gynecol Obstet 55: 570–580, 1932.Google Scholar
  3. 3.
    Hecker R, Sherlock S. Electrolyte and circulatory changes in terminal liver failure. Lancet 2: 1121–1125, 1956.CrossRefGoogle Scholar
  4. 4.
    Papper S. The role of the kidney in Laënnec’s cirrhosis of the liver. Medicine (Baltimore) 37: 299–316, 1958.Google Scholar
  5. 5.
    Papper S, Belsky JL, Bleifer KH. Renal failure in Laënnec’s cirrhosis of the liver: I. Description of clinical and laboratory features. Ann Intern Med 51: 759–773, 1959.PubMedGoogle Scholar
  6. 6.
    Vesin P. Late functional renal failure in cirrhosis with ascites: Pathophysiology, diagnosis and treatment. In Aktuelle Probleme der Hepatologie, Martini GA, Sherlock S (eds). Stuttgart: Georg Thieme Verlag, 1962, pp. 98–109.Google Scholar
  7. 7.
    Baldus WP, Feichter RN, Summerskill WHJ, Hunt JC, Wakim KG. The kidney in cirrhosis: II. Disorders of renal function. Ann Intern Med 60: 366–377, 1964.PubMedGoogle Scholar
  8. 8.
    Shear L, Kleinerman J, Gabuzda GJ. Renal failure in patients with cirrhosis of the liver: I. Clinical and pathologic characteristics. Am J Med 39: 184–198, 1965.PubMedCrossRefGoogle Scholar
  9. 9.
    Bartoli E, Chiandussi L (eds). Hepato-Renal Syndrome. Padova, Italy: Piccin Medical Books, 1979.Google Scholar
  10. 10.
    Editorial. Hepatorenal syndome or hepatic nephropathy? Lancet 1 (8172): 801-803, 1980.Google Scholar
  11. 11.
    Conn HO. A rational approach to the hepatorenal syndrome. Gastroenterology 65: 321–340, 1973.PubMedGoogle Scholar
  12. 12.
    Papper S. Renal failure in cirrhosis (the hepatorenal syndrome). In the Kidney in Liver Disease, Epstein M (ed). New York: Elsevier-North Holland, 1978, pp. 91–112.Google Scholar
  13. 13.
    Epstein M (ed). The Kidney in Liver Disease. New York: Elsevier-North Holland, 1978.Google Scholar
  14. 14.
    Vaamonde CA, Papper S. The kidney in liver disease. In Strauss and Welt’s Diseases of the Kidney (3rd ed), Earley LE, Gottschalk CW (eds). Boston: Little, Brown, and Company, 1979, pp. 1289–1317.Google Scholar
  15. 15.
    Papper S. Hepatorenal syndrome. Contri Nephrol 23: 55–74, 1980.Google Scholar
  16. 16.
    Papper S. Hepatorenal syndrome. In The Liver in Kidney Disease (2nd ed), Epstein M (ed). New York: Elsevier Science Publishing Co., Inc., 1983 pp. 87–106.Google Scholar
  17. 17.
    Koppel MH, Coburn JW, Mims MM, Goldstein H, Boyle JD, Rubini ME. Transplantation of cadaveric kidneys from patients with hepatorenal syndrome. Evidence for the functional nature of renal failure in advanced liver disease. N Engl J Med 280: 1367–1371, 1969.PubMedCrossRefGoogle Scholar
  18. 18.
    Iwatsuki S, Popovtzer MM, Corman JL, Ishikawa M, Putnam CW, Katz FH, Starzl TE. Recovery from “hepatorenal syndrome” after orthotopic liver transplantation. N Engl J Med 289: 1155–1159, 1973.PubMedCrossRefGoogle Scholar
  19. 19.
    Reynolds TB. The hepatorenal syndrome. In The Liver and Its Diseases, Schaffner F, Sherlock S, Leevy CM (eds). New York: Intercontinental Medical Book Corp, 1974, pp. 307–313.Google Scholar
  20. 20.
    Gordon JA, Anderson RJ. Hepatorenal syndrome. Seminars in Nephrology 1(1): 37–41, 1981.Google Scholar
  21. 21.
    Arras S, Faedda R, Satta A, Saggia G, Olmeo N, Bartoli E. Retrospective analysis of the incidence of the hepato-renal syndrome in patients with liver disease. In Hepato-Renal Syndrome, Bartoli E, Chiandussi L (eds). Padova, Italy: Piccin Medical Books, 1979, pp. 427–451.Google Scholar
  22. 22.
    Hall PW III, Ricanati ES. Renal handling of beta-2-microglobulin in renal disorders: With special reference to hepatorenal syndrome. Nephron 27(2): 62–66, 1981.PubMedCrossRefGoogle Scholar
  23. 23.
    Epstein M, Berk DP, Hollenberg NK, Adams DF, Chalmers TC, Abrams HL, Merrill JP. Renal failure in the patient with cirrhosis. The role of active vasoconstriction. Am J Med 49: 175–185, 1970.PubMedCrossRefGoogle Scholar
  24. 24.
    Epstein M, Schneider N, Befeler B. Relationship of systemic and intrarenal hemodynamics in cirrhosis. J Lab Clin Med 89: 1175–1187, 1977.PubMedGoogle Scholar
  25. 25.
    Berger J, Yaneva H, Nabana B. Glomerular changes in patients with cirrhosis of the liver. In Advances in Nephrology, vol. 7, Hamburger J, Crosnier J, Grunfeld J-P, Maxwell MH (eds). Chicago: Year Book Medical Publishers, 1977, pp. 3–14.Google Scholar
  26. 26.
    Wilkinson SP, Williams R. Defining “hepatorenal syndrome.” In Hepato-Renal Syndrome, Bartoli E, Chiandussi L (eds). Padova, Italy: Piccin Medical Books, 1979, pp. 21–34.Google Scholar
  27. 27.
    Wilkinson SP, Portmann B, Hurst D, Williams R. Pathogenesis of renal failure in cirrhosis and fulminant hepatic failure. Postgrad Med J 51: 503–505, 1975.PubMedCrossRefGoogle Scholar
  28. 28.
    Odell GB, Natzschka JC, Storey GNB. Bilirubin nephropathy in the Gunn strain of rat. Am J Physiol 212: 931–938, 1967.PubMedGoogle Scholar
  29. 29.
    Better OS, Berl T. Jaundice and the kidney. In The Kidney in Systemic Disease (2nd ed), Suki WN, Eknoyan G (eds). New York: John Wiley, 1981, pp. 521–537.Google Scholar
  30. 30.
    Lancestremere RG, Klingler EL Jr, Frisch E, Papper S. Simultaneous determination of cardiac output and renal function in patients with Laënnec’s cirrhosis during the administration of the pressor amine, metaraminol. J Lab Clin Med 61: 820–825, 1963.PubMedGoogle Scholar
  31. 31.
    Murray JF, Dawson AM, Sherlock S. Circulatory changes in chronic liver disease. Am J Med 24: 358–367, 1958.PubMedCrossRefGoogle Scholar
  32. 32.
    Lieberman FL, Reynolds TB. Plasma volume in cirrhosis of the liver: Its relation to portal hypertension, ascites, and renal failure. J Clin Invest 46: 1297–1208, 1967.PubMedCrossRefGoogle Scholar
  33. 33.
    Fazekas JF, Tictin HE, Ehrmantrant WR, Alman RW. Cerebral metabolism in hepatic insufficiency. Am J Med 21: 843–849, 1956.PubMedCrossRefGoogle Scholar
  34. 34.
    Tristani FE, Cohn JN. Systemic and renal hemodynamics in oliguric hepatic failure: Effect of volume expansion. J Clin Invest 46: 1894–1906, 1967.PubMedCrossRefGoogle Scholar
  35. 35.
    Epstein M. Renal sodium handling in cirrhosis: A reappraisal. Nephron 23: 211–217, 1979.PubMedCrossRefGoogle Scholar
  36. 36.
    Reynolds TB, Lieberman FL, Redeker AG. Functional renal failure with cirrhosis: The effect of plasma expansion therapy. Medicine (Baltimore) 46: 191–196, 1967.CrossRefGoogle Scholar
  37. 37.
    Barnado DE, Summerskill WHJ, Strong CG, Baldus WP. Renal function, renin activity and endogenous vasoactive substances in cirrhosis. Am J Dig Dis 15: 419–425, 1970.CrossRefGoogle Scholar
  38. 38.
    Baldus WP. Etiology and management of renal failure in cirrhosis and portal hypertension. Ann NY Acad Sci 170: 267–278, 1969.CrossRefGoogle Scholar
  39. 39.
    Lancet Paris Correspondent. The antitoxin functions of the liver. Lancet 2: 1092–1093, 1893.Google Scholar
  40. 40.
    Shorr E. Hepatorenal vasotropic factors in experimental cirrhosis. In Transactions of the 6th Conference on Liver Injury, May 1–2, 1947. New York: Josiah Macy Foundation, 1947, pp. 33-39.Google Scholar
  41. 41.
    Kew MC, Limbrick CA, Varma RR, Williams HS, Sherlock S. Renal blood flow in malignant disease of the liver. Gut 13: 421–426, 1972.PubMedCrossRefGoogle Scholar
  42. 42.
    Bloom D, McCalden TA, Rosendorff C. Effects of jaundiced plasma on vascular sensitivity to noradrenalin. Kidney Int 8: 149–157, 1975.PubMedCrossRefGoogle Scholar
  43. 43.
    Baum M, Stirling GA, Dawson JL. Further study into obstructive jaundice and ischemic renal damage. Br Med J 2: 229–231, 1969.PubMedCrossRefGoogle Scholar
  44. 44.
    Dawson JL. Jaundice and anorexic renal damage: Protective effect of mannitol. Br Med J 1: 810–811, 1964.PubMedCrossRefGoogle Scholar
  45. 45.
    Mashford ML, Mahon WA, Chalmers TC. Studies of the cardiovascular system in the hypotension of liver failure. N Engl J Med 267: 1071–1074, 1962.PubMedCrossRefGoogle Scholar
  46. 46.
    Fischer JE, Baldessarini RJ. False neurotransmitters and hepatic failure. Lancet 2: 75–80, 1971.PubMedCrossRefGoogle Scholar
  47. 47.
    Gillenwater JY, Dooley ES, Frohlich ED. Effects of endotoxin on renal function and hemodynamics. Am J Physiol 205: 293–297, 1963.PubMedGoogle Scholar
  48. 48.
    Clemente C, Rodes J, Bosch J, Arroyo V, Mas A, Teres J. Functional renal failure in cirrhosis. A possible role for endotoxin? Digestion (abstract) 12: 295, 1975.Google Scholar
  49. 49.
    Gatta A, Milani L, Merkel C, Amodio P, Caregaro L, Zuin R (letter to editor). Lancet 2(8237): 101–102, 1981.Google Scholar
  50. 50.
    Fulenwider, JT, Sibley C, Stein SF, Evatt B, Nordlinger BM, Ivey GL. Endotoxemia in cirrhosis; an observation not substantiated. Gastroenterology 78: 1001–1004, 1980.PubMedGoogle Scholar
  51. 51.
    Berkowitz HD, Miller LD, Rosato E. Renin substrate depletion in the hepatorenal syndrome. N Engl J Med 290: 461, 1974.PubMedGoogle Scholar
  52. 52.
    Elkin M, Meng CH. The effects of angiotensin on renal vascularity in dogs. Am J Roentgenol 98: 927–934, 1966.Google Scholar
  53. 53.
    Arroyo V, Bosch J, Rodes J. The renin-angiotensin system in cirrhosis. In Hepato-Renal Syndrome, Bartoli E, Chiandussi L (eds). Padova, Italy: Piccin Medical Books, 1979, pp. 201–227.Google Scholar
  54. 54.
    Schroeder ET, Anderson GH Jr, Smulyan H. Effects of portacaval or peritoneovenous shunt on renin in the hepatorenal syndrome. Kidney Int 15: 54–61, 1979.PubMedCrossRefGoogle Scholar
  55. 55.
    Zipser RD, Hoefs JC, Speckart PF, Zia PK, Horton R. Prostaglandins: Modulators of renal function and pressor resistance in chronic liver disease. J Clin Endocrinol Metab 48: 895–900, 1979.PubMedCrossRefGoogle Scholar
  56. 56.
    Zusman RM, Axelrod L, Tolkoff-Rubin N. The treatment of the hepatorenal syndrome with intrarenal administration of prostaglandin E1. Prostaglandins 13: 819–830, 1977.PubMedCrossRefGoogle Scholar
  57. 57.
    Boyer TD, Zia P, Reynolds TB. Effect of indomethacin and prostaglandin A1 on renal function plasma renin activity in alcoholic liver disease. Gastroenterology 77: 215–222, 1979.PubMedGoogle Scholar
  58. 58.
    Said SI, Mutt V. Polypeptide with broad biological activity: Isolation from small intestine. Science 169: 1217–1218, 1970.PubMedCrossRefGoogle Scholar
  59. 59.
    Hunt S, Vaamonde CA, Rattassi T, Berian G, Said SI, Papper S. Circulating levels of vasoactive intestinal polypeptide in liver disease. Arch Intern Med 139: 994–996, 1979.PubMedCrossRefGoogle Scholar
  60. 60.
    Espinel CH, Said SI, Maklouf GM. Different effects of the peptide homologues, VIP (vasoactive intestinal polypeptide) and glucagon on renal transport and hemodynamics (abstract). Clin Res 24: 36A, 1976.Google Scholar
  61. 61.
    Wong PY, Talamo RC, Williams GH. Kallikreinkinin and renin-angiotensin systems in functional renal failure of cirrhosis of the liver. Gastroenterol 73: 1114–1118, 1977.Google Scholar
  62. 62.
    Thurau K, Schnermann J. Die Natriumkonzentration an den Macula densa-Zellen als regulierender Faktor fur das Glomerulumfiltrat. Klin Wochenschr 43: 410–413, 1965.PubMedCrossRefGoogle Scholar
  63. 63.
    Wunderlich PF, Brunner FP, Davis JM, Haberle, DA, Tholen H, Thiel G. Feedback activation in rat nephrons by sera from patients with acute renal failure. Kidney Int 17: 497–506, 1980.PubMedCrossRefGoogle Scholar
  64. 64.
    Perez GO, Oster JR. A critical review of the role of dialysis in the treatment of liver disease. In The Kidney in Liver Disease, Epstein M (ed). New York: Elsevier-North Holland, 1978, pp. 325–336.Google Scholar
  65. 65.
    Levy VG, Opolon P, Pauleau N, Caroli J. Treatment of ascites by reinfusion of concentrated peritoneal fluid—review of 318 procedures in 210 patients. Postgrad Med J 51: 564–566, 1975.PubMedCrossRefGoogle Scholar
  66. 66.
    Wilkinson SP, Weston MJ, Parsons V, Williams R. Dialysis in the treatment of renal failure in patients with liver disease. Clin Nephrol 8: 287–292, 1977.PubMedGoogle Scholar
  67. 67.
    Ring-Larsen H, Clausen E, Ranek L. Peritoneal dialysis in hyponatremia due to liver failure. Scand J Gastroenterol 8: 33–40, 1973.PubMedGoogle Scholar
  68. 68.
    Krumlovsky FA, del Greco F, Niederman M. Prolonged hemoperfusion and hemodialysis in management of hepatic failure and hepatorenal syndrome. Trans Am Soc Artif Intern Organs 24: 235–238, 1978.PubMedGoogle Scholar
  69. 69.
    Wilkinson SP. Endotoxins and liver disease. Scand J Gastroenterol 12: 385–386, 1977.PubMedCrossRefGoogle Scholar
  70. 70.
    Arieff AI, Chidsey CA. Renal function in cirrhosis and the effects of prostaglandin A1. Am J Med 56: 695–703, 1974.PubMedCrossRefGoogle Scholar
  71. 71.
    Schroeder ET, Numann PJ, Chamberlain BE. Functional renal failure in cirrhosis. Recovery after protocaval shunt. Ann Intern Med 72: 923–928, 1970.PubMedGoogle Scholar
  72. 72.
    Garrett JG, Voorhees AB Jr, Sommers SC. Renal failure following portasystemic shunt in patients with cirrhosis of the liver. Ann Surg 172: 218–225, 1970.PubMedCrossRefGoogle Scholar
  73. 73.
    Ring-Larsen H, Hesse B, Stigsby B. Effect of portal systemic anastomosis on renal hemodynamics in cirrhosis. Gut 17: 856–860, 1976.PubMedCrossRefGoogle Scholar
  74. 74.
    Grosberg SJ, Wapnick S. A retrospective comparison on functional renal failure in cirrhosis treated by conventional therapy or the peritoneovenous shunt (LeVeen). Am J Med Sci 276: 287–291, 1978.PubMedCrossRefGoogle Scholar
  75. 75.
    Plodson TR, Panish RM. Hepatorenal syndrome: Recovery after peritoneovenous shunt. Arch Intern Med 137; 1248–1249, 1977.CrossRefGoogle Scholar
  76. 76.
    Berkowitz, HD, Mullen JL, Miller LD, Rosato EF. Improved renal function and inhibition of renin and aldosterone secretion following peritoneovenous (LeVeen) shunt. Surgery 84: 120–126, 1978.PubMedGoogle Scholar
  77. 77.
    Witte MH, Witte CL, Jacobs S, Kut R. Peritoneovenous (LeVeen) shunt: Control of renin-aldosterone system in cirrhotic ascites. JAMA 239: 31–33, 1978.PubMedCrossRefGoogle Scholar
  78. 78.
    Epstein M. The peritoneovenous shunt in the management of ascites and the hepatorenal syndrome. Gastroenterol 82: 790–799, 1982.Google Scholar

Copyright information

© Martinus Nijhoff Publishing, Boston 1984

Authors and Affiliations

  • Solomon Papper

There are no affiliations available

Personalised recommendations